Q-omics provides the consensus-scored TMEM164 profile across patient tissues and cancer cell-line models. TMEM164 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TMEM164 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TMEM164 RNA expression shows 19,186 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, KIRC, and UVM as cancer lineages where TMEM164 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM164 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM164 survival associations across molecular data types. TMEM164 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM164 RNA expression–survival associations across cancer types. High TMEM164 expression shows unfavorable associations in LIHC, KIRP, UCEC, LUAD and KICH, but favorable associations in SCLC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TMEM164 RNA expression.
This table summarizes TMEM164 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM164. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM164 shows lower tumor expression in KIRC, THCA, LUAD and KICH and higher tumor expression in LIHC and STAD. The KIRC box plot shows higher TMEM164 RNA expression in normal versus tumor tissue (log2 FC = −1.379, t-test p < 0.001).
This table shows molecular features associated with TMEM164 in patient tissues and cancer cell lines. In patient samples, TMEM164 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM164 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
